4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Advanced Immunization Technologies (ADITEC)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet
53
Participants partenaires
TERMINÉ
Vaccination against Shigella and ETEC: novel antigens, novel approaches (STOPENTERICS)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2017,
To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel solutions by imposing a two-fold paradigm switch: (i) to break the dogma of serotype-specificity by inducing a cross-protective immunity (ii) to improve the immunogenicity of Shigella glycoconjugates by using synthetic oligosacharides mimicking the lipopolysa ...
Voir le projet
20
Participants partenaires
TERMINÉ
Combined Highly Active Anti-retroviral Microbicides (CHAARM)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,
This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of r ...
Voir le projet
34
Participants partenaires
TERMINÉ
Use of a Multidrug Pill In Reducing cv Events (UMPIRE)
Date du début: 1 févr. 2010, Date de fin: 31 janv. 2013,
"Cardiovascular disease is the focus of this proposal as it is the leading cause of mortality worldwide. People with established vascular disease represent a target for secondary prevention using combination therapy that addresses multiple risk factors. Barriers to effective delivery of proven secondary preventative treatments create important gaps in the uptake. These gaps vary in different count ...
Voir le projet